

Financial news for TBPH dated on 2020-05-13: Benzinga's Top Upgrades, Downgrades For May 13, 2020

Financial news for TBPH dated on 2020-05-13: Cowen & Co. Initiates Coverage On Theravance Biopharma with Outperform Rating, Announces Price Target of \$42

Financial news for TBPH dated on 2020-05-06: Theravance Biopharma Q1 EPS \$(1.400) Misses \$(1.070) Estimate, Sales \$19.900M Beat \$18.130M Estimate

Financial news for TBPH dated on 2020-05-06: The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle

Financial news for TBPH dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for TBPH dated on 2020-04-23: Theravance Biopharma Reports First Subject Dosed In Phase 1 Study Of TD-0903 In Development for the Treatment of Hospitalized Patients with Acute Lung Injury Caused by COVID-19

Financial news for TBPH dated on 2020-04-20: Theravance Biopharma Announces Peer-Reviewed Publication Highlighting TD-1473 Program in the Journal of Crohn's and Colitis

Financial news for TBPH dated on 2020-04-09: Theravance Biopharma Highlights Clinical Trial Application Submitted In UK for First In Human Study Of TD-9003 For Acute Lung Injury Related To Coronavirus

Financial news for TBPH dated on 2020-02-25: HC Wainwright & Co. Maintains Buy on Theravance Biopharma, Raises Price Target to \$32

Financial news for TBPH dated on 2020-02-25: Piper Sandler Maintains Overweight on Theravance Biopharma, Lowers Price Target to \$35

Financial news for TBPH dated on 2020-02-24: Theravance Biopharma Q4 EPS \$(1.17) Misses \$(1.13) Estimate

Financial news for TBPH dated on 2020-02-23: The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace

Financial news for TBPH dated on 2020-02-13: 60 Biggest Movers From Yesterday

Financial news for TBPH dated on 2020-02-12: 52 Stocks Moving In Wednesday's Mid-Day Session

Financial news for TBPH dated on 2020-02-12: 31 Stocks Moving in Wednesday's Pre-Market Session

Financial news for TBPH dated on 2020-02-12: 94 Biggest Movers From Yesterday

Financial news for TBPH dated on 2020-02-12: Theravance Biopharma Prices 5.5M Stock Offering @\$27/Share

Financial news for TBPH dated on 2020-02-11: 71 Stocks Moving In Tuesday's Mid-Day Session

Financial news for TBPH dated on 2020-02-11: The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology

Financial news for TBPH dated on 2020-02-11: 36 Stocks Moving in Tuesday's Pre-Market Session

Financial news for TBPH dated on 2020-02-11: 10 Stocks To Watch For February 11, 2020

Financial news for TBPH dated on 2020-02-10: 20 Stocks Moving In Monday's After-Hours Session

Financial news for TBPH dated on 2020-02-10: Theravance Biopharma shares are trading lower after the company announced a \$150 million proposed offering of ordinary shares.

Financial news for TBPH dated on 2020-02-10: Theravance Biopharma Announces \$150M Proposed Public Offering of Ordinary Shares

Financial news for TBPH dated on 2020-02-06: The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs

Financial news for TBPH dated on 2020-02-05: Stocks That Hit 52-Week Highs On Wednesday

Financial news for TBPH dated on 2020-02-05: The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data

Financial news for TBPH dated on 2020-02-04: Stocks That Hit 52-Week Highs On Tuesday

Financial news for TBPH dated on 2020-02-04: The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares

Financial news for TBPH dated on 2020-02-03: Stocks That Hit 52-Week Highs On Monday

Financial news for TBPH dated on 2019-12-23: Theravance Biopharma And Pfizer Inc. Enter Global License Agreement For Skin-Targeted, Locally-Acting Pan-Janus Kinase Inhibitor Program; Theravance To Receive Upfront Cash Payment Of \$10M And Up To \$240M In Milestones

Financial news for TBPH dated on 2019-12-03: Theravance Biopharma Doses First Patient In Phase 2 Allergen Challenge Study Of TD-8236, An Investigational, Lung-Selective, Inhaled Pan-Janus Kinase Inhibitor For Inflammatory Lung Diseases

Financial news for TBPH dated on 2019-11-06: Benzinga's Top Upgrades, Downgrades For November 6, 2019

Financial news for TBPH dated on 2019-11-06: Baird Upgrades Theravance Biopharma to Neutral, Lowers Price Target to \$18

Financial news for TBPH dated on 2019-11-05: Theravance Biopharma Q3 EPS \$(1.05) Beats \$(1.11) Estimate, Sales \$12.427M Beat \$11.62M Estimate

Financial news for TBPH dated on 2019-11-05: The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment

Financial news for TBPH dated on 2019-10-29: Benzinga's Top Upgrades, Downgrades For October 29, 2019

Financial news for TBPH dated on 2019-10-29: HC Wainwright & Co. Initiates Coverage On Theravance Biopharma with Buy Rating, Announces \$25 Price Target

Financial news for TBPH dated on 2019-09-09: Theravance Biopharma Reports 'Positive' Results from its Phase 1 Clinical Trial of TD-8236

Financial news for TBPH dated on 2019-08-20: UK's Woodford Equity Income Fund Suspended

Financial news for TBPH dated on 2019-07-31: Theravance Biopharma Q2 EPS \$(0.72) Beats \$(1.24) Estimate, Sales \$26.15M Beat \$10.87M Estimate

Financial news for TBPH dated on 2019-07-22: Theravance Biopharma Reports New Data From Phase 2 Study Of Amprexetine (TD-9855) In Oral Presentation At 32nd European Neurology Congress

Financial news for TBPH dated on 2019-06-18: Theravance Biopharma Presents New Data From Phase 2 Study Of Amprexetine At 2019 International Association Of Parkinsonism And Related Disorders (IAPRD) World Congress

Financial news for TBPH dated on 2019-06-15: The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs

Financial news for TBPH dated on 2019-06-14: Theravance Biopharma and Mylan Expand YUPELRI Development and Commercialization Agreement to Include China and Adjacent Territories, Theravance to Receive a \$18.5M Upfront Payment

Financial news for TBPH dated on 2019-06-07: The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix

Financial news for TBPH dated on 2019-06-06: The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering

Financial news for TBPH dated on 2019-06-04: Theravance Biopharma Names Andrew Hindman CFO

Financial news for TBPH dated on 2019-05-31: The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering

Financial news for TBPH dated on 2019-05-30: The Daily Biotech Pulse: Unity Biotech Licenses Anti-Aging Protein, Strong Results For Mereo's Brittle Bone Disease Drug

Financial news for TBPH dated on 2019-05-29: The Daily Biotech Pulse: Inovio's Partner Scales Back R&D Collaboration, Genmab Seeks Nasdaq Listing, Bayer Gets Breakthrough Therapy Designation

Financial news for TBPH dated on 2019-05-24: The Daily Biotech Pulse: FDA Nod For Novocure, Dynavax Restructures, Therapix Receives Nasdaq Notice

Financial news for TBPH dated on 2019-05-22: The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study

Financial news for TBPH dated on 2019-05-21: The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails

Financial news for TBPH dated on 2019-05-21: Theravance Biopharma To Present Data From Phase 1b Study Of TD-1473 At Digestive Disease Week 2019

Financial news for TBPH dated on 2019-05-20: Theravance Biopharma, Mylan Report Presentation Of Data From Pivotal Phase 3 Efficacy Studies, 52-Week Safety Study At American Thoracic Society

Financial news for TBPH dated on 2019-05-14: Theravance Biopharma Announces Data From Phase 1b Study Of TD-1473 To Be Featured In Oral Presentation At Digestive Disease Week (DDW) 2019

Financial news for TBPH dated on 2019-05-07: Theravance Biopharma Q1 EPS \$(1.32) Misses \$(1.19) Estimate, Sales \$5.338M Miss \$16.21M Estimate

Financial news for TBPH dated on 2019-04-17: Shares of several healthcare companies are trading lower after Trump renewed his efforts to repeal and replace the Affordable Care Act; the Department of Justice moved to accelerate the appeal process in hopes to invalidate the ACA as unconstitutional.

Financial news for TBPH dated on 2019-03-25: Theravance Biopharma Announces Amprexetine Phase 2 Study Results Selected for Oral Presentation at 32nd European Neurology Congress

Financial news for TBPH dated on 2019-03-12: Theravance Biopharma Announces First Patient Dosed In Phase 2b/3 Study Of TD-1473 In Patients with Ulcerative Colitis

Financial news for TBPH dated on 2019-02-26: Theravance Biopharma Q4 EPS \$(0.92) Beats \$(1.06) Estimate, Sales \$15.737M Miss \$23.43M Estimate

Financial news for TBPH dated on 2019-02-26: The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote

Financial news for TBPH dated on 2019-01-28: Theravance Biopharma Announces First Patient Dosed In Registrational Phase 3 Study Of Amprexetine (TD-9855) For The Treatment Of Symptomatic Neurogenic Orthostatic Hypotension

Financial news for TBPH dated on 2018-11-27: Theravance Biopharma Announces First Subject Dosed In Phase 1 Clinical Trial Of TD-8236, A Novel Inhaled pan-JAK Inhibitor

Financial news for TBPH dated on 2018-11-20: Theravance Biopharma Reports First Patient Dosed In Phase 2 Study Of TD-1473 In Patients With Crohn's Disease

Financial news for TBPH dated on 2018-11-11: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for TBPH dated on 2018-11-09: Theravance, Mylan Press Release Confirms Received FDA Approval For YUPELRI In Adults With Chronic Obstructive Pulmonary Disease

Financial news for TBPH dated on 2018-11-09: UPDATE: FDA Access Data Doc Shows Medication Guide For Theravance, Mylan's YUPELRI Was Approved By FDA

Financial news for TBPH dated on 2018-11-09: Traders Circulate FDA Access Data Doc Showing Highlights Of Prescribing Information For Theravance, Mylan's YUPELRI

Financial news for TBPH dated on 2018-11-06: Theravance Biopharma Q3 EPS \$(1.10) Beats \$(1.15) Estimate, Sales \$12.838M Miss \$14.06M Estimate

Financial news for TBPH dated on 2018-11-06: Cumberland Pharma To Purchase VIBATIV From Theravance Biopharma For \$20M Plus \$5M In Added Payment In Early 2019, Tiered Royalties Of Up To 20% On Future US Net Product Sales

Financial news for TBPH dated on 2018-11-06: The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering

Financial news for TBPH dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for TBPH dated on 2018-10-22: Theravance Biopharma Reports Presentation Of Data From TD-1473 Phase 1b 4-Week Study In Oral Late-Breaker Presentation At United European Gastroenterology Week

Financial news for TBPH dated on 2018-10-11: Theravance Biopharma Mylan Reported Positive Data From Multiple Studies Of YUPELRI At 2018 CHEST Annual Meeting

Financial news for TBPH dated on 2018-10-08: Theravance Biopharma And Mylan To Present New Data From Studies Of YUPELRI At 2018 CHEST Annual Meeting

Financial news for TBPH dated on 2018-10-08: Theravance Biopharma Reports 'Positive' New Data from Multiple Studies of VIBATIV at IDWeek 2018

Financial news for TBPH dated on 2018-10-04: Theravance Biopharma In 8-K Says On Oct. 3, CFO Renee D. Gala Notified Co. Of Resignation As On Jan. 2, 2019

Financial news for TBPH dated on 2018-10-01: Theravance Biopharma To Present New Data From Multiple Studies Of VIBATIV (telavancin) At IDWeek 2018 Oct. 3-7

Financial news for TBPH dated on 2018-09-24: Theravance Biopharma Highlights Positive CHMP Opinion Supporting Expanded COPD Indication for Trelegy Ellipta in Europe

Financial news for TBPH dated on 2018-09-16: The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for TBPH dated on 2018-09-12: Theravance Biopharma shares are down 1.1% as traders circulate ClinicalTrials.gov document showing Phase Telavancin was terminated due to lack of statistical power; No safety concerns identified.

Financial news for TBPH dated on 2018-09-12: Watching Thervance Biopharma Shares As Traders Circulating ClinicalTrials.gov Doc Showing Phase 3 Telavancin Trial Terminated 'due to lack of statistical power'

Financial news for TBPH dated on 2018-08-10: Form 4 Filing Late Thursday Showed Theravance Biopharma EVP Bradford Shafer Sold a Total of 31.3K Shares at Avg. Prices Ranging From \$27.63-\$29.28

Financial news for TBPH dated on 2018-08-01: UPDATE: Piper Jaffray On Thervance Says 'It Looks Like Theravance Has A New \$500M+ Drug'

Financial news for TBPH dated on 2018-08-01: Theravance Biopharma Q2 EPS \$(0.76) Beats \$(1.20) Estimate, Sales \$23.48M Beat \$10.67M Estimate

Financial news for TBPH dated on 2018-08-01: Theravance Biopharma Reports Top-Line Four-Week Data From Phase 2 Trial of TD-9855 For Treatment of Symptomatic Neurogenic Orthostatic Hypotension

Financial news for TBPH dated on 2018-05-29: Theravance Biopharma Announces Submission of Regulatory Application in Japan for Trelegy Ellipta

Financial news for TBPH dated on 2018-05-19: Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching

Financial news for TBPH dated on 2018-04-25: Theravance Biopharma Highlights Approval of Expanded Indication in the US for Once-Daily Trelegy Ellipta for Treatment of COPD Patients

Financial news for TBPH dated on 2018-04-23: Theravance Biopharma Reports 'Positive' New Data from Multiple Studies of VIBATIV at 2018 ECCMID Conference

Financial news for TBPH dated on 2018-02-27: Theravance Biopharma Reports Q4 EPS \$(1.64) vs \$(1.36) In Same Qtr. Last Year, Sales \$4.515M

Financial news for TBPH dated on 2018-02-27: Theravance Biopharma Q4 Earnings Outlook

Financial news for TBPH dated on 2018-02-15: Theravance Biopharma Reports Submission Of IMPACT Data To EMA For Supporting Of Expanded Label For Trelegy Ellipta

Financial news for TBPH dated on 2018-02-08: 30 Biggest Movers From Yesterday

Financial news for TBPH dated on 2018-02-07: 33 Stocks Moving In Wednesday's Mid-Day Session

Financial news for TBPH dated on 2018-02-07: Theravance Biopharma Reports Entered Global Collaboration With J&J's Janssen For TD-1473 In Inflammatory Intestinal

Diseases

Financial news for TBPH dated on 2018-01-29: Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin, FDA Assigns PDUFA Target Action Date of November 13, 2018

Financial news for TBPH dated on 2017-11-28: Theravance Biopharma Highlights Submission of Landmark IMPACT Data to FDA to Support Expanded Label for Trelegy Ellipta

Financial news for TBPH dated on 2017-11-16: Theravance Biopharma Highlights Marketing Authorization in Europe for Trelegy Ellipta, Launch of Trelegy Ellipta in Europe Expected Before End of Year

Financial news for TBPH dated on 2017-11-13: Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin in Adults with Chronic Obstructive Pulmonary Disease

Financial news for TBPH dated on 2017-11-07: Theravance Biopharma Reports Q3 EPS \$(1.27) vs \$(1.20) Est., Sales \$4.275M vs \$4.61M Est.

Financial news for TBPH dated on 2017-11-01: Theravance, Mylan To Offer Added Phase 3 Data For TD-4208 At CHEST: 'Presentations Highlight 24-Hour Serial Spirometry Subgroup Findings from 2 Replicate Pivotal Phase 3 Studies; Improvements Observed in St. George's Respiratory Questionnaire...'

Financial news for TBPH dated on 2017-10-31: Theravance Biopharma Says Preliminary Findings Demonstrate Clinical Response Rates with VIBATIV (telavancin) Treatment for Patients with Lower Respiratory Tract Infections

Financial news for TBPH dated on 2017-10-09: Theravance Biopharma Reports 'Positive' New Data from Multiple Studies of VIBATIV

Financial news for TBPH dated on 2017-09-20: Theravance Biopharma, GlaxoSmithKline and Innoviva Announce IMPACT Study Shows Trelegy Ellipta Met Its Primary Endpoint With Statistical Significance

Financial news for TBPH dated on 2017-09-19: Theravance Biopharma Highlights Approval of Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US, Is Entitled To Receive 85% Economic Interest In Trelegy Ellipta Royalties

Financial news for TBPH dated on 2017-09-18: Theravance Biopharma Highlights GlaxoSmithKline and Innoviva's Receipt of Positive Opinion from CHMP in Europe for Trelegy Ellipta, Is Entitled To Receive 85% Economic Interest In Closed Triple Royalties Paid By GSK

Financial news for TBPH dated on 2017-08-17: Evercore ISI Group Initiates Coverage On Theravance Biopharma, Inc. - Ordinary Shares with Outperform Rating

Financial news for TBPH dated on 2017-08-08: Theravance Biopharma Reports Q2 Loss/Share \$(1.27) vs. \$(1.14) Est., Sales \$3.5M vs. \$4.66M Est.

Financial news for TBPH dated on 2017-08-02: Theravance Biopharma Reports Top-Line Results from Phase 2b Study of Velusetrag (TD-5108) in Patients with Gastroparesis

Financial news for TBPH dated on 2017-07-19: Theravance, Mylan Report Results of Phase 3 TD-4208 Study 'demonstrated that revefenacin was generally well-tolerated, and no new safety issues were identified'

Financial news for TBPH dated on 2017-07-19: Theravance Biopharma, Mylan Report Results From 12-Month Phase 3 Safety Study Of TD-4208 In Patients With COPD: Data Supports NDA Filing Expected For Q4'17

Financial news for TBPH dated on 2017-06-16: Cantor Fitzgerald Initiates Coverage On Theravance Biopharma, Inc. - Ordinary Shares with Overweight Rating, Announces \$55.00 Price Target

Financial news for TBPH dated on 2017-06-05: Theravance Says VIBATIV (telavancin) Demonstrates Greater in vitro Activity Compared to Competitor Antibiotics Against Range of Challenging Infection Types

Financial news for TBPH dated on 2017-05-09: Theravance Reaffirms FY17 Operating Loss \$205M-\$195M

Financial news for TBPH dated on 2017-05-09: UPDATE: Theravance Biopharma Reports Q1 Sales \$3.08M vs \$5.5M Est.

Financial news for TBPH dated on 2017-05-09: Theravance Biopharma Reports Q1 EPS

\$(1.27) vs \$(1.14) Est.

Financial news for TBPH dated on 2017-04-24: Theravance Biopharma Reports Positive Clinical Response Rates for Patients in TOUR Patient Registry: VIBATIV Response Rates Treatment Range 58-75%

Financial news for TBPH dated on 2017-04-18: Theravance Biopharma Announces Prelim. Data from TOUR Highlights Which Show Positive Clinical Response Rate Across Several Difficult-to-Treat Infection Types

Financial news for TBPH dated on 2017-02-27: Theravance Biopharma Reports Q4 EPS \$(1.36) vs. \$(1.05) Est., Sales \$5.69M vs. \$4.9M Est.

Financial news for TBPH dated on 2017-02-17: Theravance Biopharma Reports Clinical Data on TD-1473: Further Data from Phase 1 Trial Reaffirms Favorable Tolerability of Single and Multiple Oral Doses of TD-1473 and Minimal Systemic Exposure in Healthy Subjects

Financial news for TBPH dated on 2017-02-09: How To Invest Like Seth Klarman

Financial news for TBPH dated on 2017-01-23: Theravance Biopharma Reports New Data from Ongoing TOUR Observational Patient Registry: Show VIBATIV Generates Positive Clinical Response Rate of ~65% for Patients with Bacteremia or Infective Endocarditis

Financial news for TBPH dated on 2017-01-09: Theravance Biopharma Says Royalties from 'Closed Triple' Expected as Early as 2018

Financial news for TBPH dated on 2016-12-19: Theravance Says is Entitled to Receive 85% Economic Interest in Closed Triple Royalties Paid by GSK as Part of Agreement with Innoviva

Financial news for TBPH dated on 2016-12-14: Theravance Shares Sell Off as \$31 Support Level Breaks, Down ~\$0.90 Over Last Min, Down ~5% for Session

Financial news for TBPH dated on 2016-12-06: Theravance Biopharma Receives FDA Fast Track Designation For Velusetrag

Financial news for TBPH dated on 2016-12-05: Theravance Biopharma Highlights Filing of EU Regulatory Submission for the Closed Triple in COPD by GlaxoSmithKline and Innoviva, Will Receive 85% Economic Interest In Closed Triple Royalties Paid By GSK As Part Of Agreement

Financial news for TBPH dated on 2016-11-21: Theravance Biopharma Highlights Filing of U.S. New Drug Application for the Closed Triple in COPD by GlaxoSmithKline and Innoviva

Financial news for TBPH dated on 2016-11-11: Theravance Biopharma Spikes to High of \$33.43 on Volume

Financial news for TBPH dated on 2016-11-08: Theravance Biopharma Reports Q3 Loss/Share \$0.73 vs Est Loss/Share \$0.92, Revenue \$19.1M vs \$12.62M Est

Financial news for TBPH dated on 2016-11-03: Benzinga's Top Initiations

Financial news for TBPH dated on 2016-11-03: The Market In 5 Minutes: Facebook Beats, First Solar Falls And A 108-Year Drought Ends

Financial news for TBPH dated on 2016-11-03: PiperJaffray Initiates Coverage On Theravance Biopharma, Inc. - Ordinary Shares at Overweight, Announces \$42.00

Financial news for TBPH dated on 2016-10-31: Theravance Says 'TOUR Results Highlight Clinical Response Rates for VIBATIV(r) (telavancin) in a Range of Difficult-to-Treat Infections'

Financial news for TBPH dated on 2016-10-28: Theravance Biopharma Prices 3.85M Share Offering @\$26.00/Share

Financial news for TBPH dated on 2016-10-26: Theravance Biopharma Announces Proposed Public Offerings of \$100 Million of Ordinary Shares

Financial news for TBPH dated on 2016-10-25: Theravance Biopharma Announces Positive Results Including Biomarker Data from Phase 1 Multiple-Ascending Dose Study of TD-0714

Financial news for TBPH dated on 2016-10-20: Theravance Biopharma and Mylan Say Revefenacin Phase 3 Study Met Primary Endpoints

Financial news for TBPH dated on 2016-10-12: Theravance Biopharma's Valuation Has Gotten A Little Carried Away

Financial news for TBPH dated on 2016-10-12: 12 Biggest Mid-Day Losers For Wednesday

Financial news for TBPH dated on 2016-10-12: Mid-Morning Market Update: Markets Mostly Flat; Stanley Black & Decker To Buy Newell Tool Unit For \$1.95B

Financial news for TBPH dated on 2016-10-12: The Market In 5 Minutes: Fed Focus, British Pound, More Earnings

Financial news for TBPH dated on 2016-10-12: Benzinga's Top Downgrades

Financial news for TBPH dated on 2016-10-12: Baird Downgrades Theravance Biopharma, Inc. to Underperform

Financial news for TBPH dated on 2016-10-04: Theravance Biopharma Reports Initial Subject Dosed in Phase 1b Clinical Trial of TD-1473 in Patients With Moderate to Severe Ulcerative Colitis

Financial news for TBPH dated on 2016-09-07: UPDATE: Theravance Says GSK's Regulatory Submissions On Track for Closed Triple in US, Europe by End of '16

Financial news for TBPH dated on 2016-09-07: UPDATE: Theravance Biopharma Says Will Be Entitled to Receive 85% Economic Interest in Closed Triple Royalties Paid by GSK as Part of Deal with Innoviva

Financial news for TBPH dated on 2016-09-07: Theravance Biopharma Announces Clinically Meaningful Benefits For The Closed Triple

Financial news for TBPH dated on 2016-08-29: Benzinga's Top Initiations

Financial news for TBPH dated on 2016-08-29: Evercore ISI Group Initiates Coverage on Theravance Biopharma at Buy, Announces \$41.00 PT

Financial news for TBPH dated on 2016-08-08: Theravance Biopharma Reports Q2 EPS \$(1.06) vs. Est. \$(1.05), Rev. \$5.47M vs. Est. \$12.7M

Financial news for TBPH dated on 2016-08-03: The Market In 5 Minutes: Downtrend Continues

Financial news for TBPH dated on 2016-08-03: Bank of America Downgrades Theravance Biopharma to Underperform

Financial news for TBPH dated on 2016-06-20: Theravance Biopharma Highlights Positive Top-Line Results from Pivotal Phase 3 FULFIL Study of Closed Triple Announced by GlaxoSmithKline, Innoviva

Financial news for TBPH dated on 2016-06-20: Theravance Biopharma Reports New Positive Data From Several VIBATIV Studies

Financial news for TBPH dated on 2016-06-20: Guggenheim Securities Initiates Coverage on Theravance Biopharma at Buy

Financial news for TBPH dated on 2016-06-08: Theravance Announces Takeda Has Licensed Global Rights to Co.'s TD-8954

Financial news for TBPH dated on 2016-05-16: Theravance Biopharma Reports Phase 3 ATTAIN Trials Shows No Statistically Significant Differences In Nephrotoxicity & Morbidity For Telavancin vs. Vancomycin

Financial news for TBPH dated on 2016-05-09: Theravance Biopharma Reports Q1 EPS \$(1.10) Vs Est \$(0.96), Sales \$18.41M Vs Est \$18.69M

Financial news for TBPH dated on 2016-05-09: Theravance Biopharma Announces FDA Approval of Expanded Label for VIBATIV

Financial news for TBPH dated on 2016-05-05: Bank of America Downgrades Theravance Biopharma to Neutral

Financial news for TBPH dated on 2016-04-27: Theravance Biopharma Announces Proposed Public Offering 4.25M Ordinary Shares

Financial news for TBPH dated on 2016-04-11: Theravance Biopharma Shows Greater In Vitro Potency vs. Other Antibiotic Treatments For Difficult-to-Treat Pathogens

Financial news for TBPH dated on 2016-04-04: Theravance Biopharma To Show New Data Demonstrating Strong In Vitro Activity For VIBATIV Against Difficult-to-Treat Infections At 2016 ECCMID

Financial news for TBPH dated on 2016-03-24: Theravance Biopharma Holder

GlaxoSmithKline Reports 24.3% Stake As Of March 14

Financial news for TBPH dated on 2016-03-18: Theravance Biopharma Presents Positive Results From a Preclinical Colitis Model for TD-1473, Showed To Be Significant Pan-JAK Inhibitor

Financial news for TBPH dated on 2016-03-14: Theravance Biopharma And Glaxo Group Enter Agreement Where Theravance To Sell 1.3M Shares At \$17.70/Share For \$23M

Financial news for TBPH dated on 2016-03-09: Theravance Biopharma Reports Q4 Rev. \$3.893M

Financial news for TBPH dated on 2016-03-09: Theravance Biopharma Reports Q4 EPS \$(1.23) vs. Est. \$(1.62)

Financial news for TBPH dated on 2016-03-09: Theravance Biopharma Announces Positive Results Including Biomarker Data From Phase 1 Study of TD-0714, an Inhibitor of Neprilysin, Study Shows Maximal & Sustained Target Enhancement

Financial news for TBPH dated on 2016-01-26: Theravance Biopharma Announces Launch Of New Drug In Canada; Investors Shrugging Off News

Financial news for TBPH dated on 2016-01-26: Theravance Biopharma Reports Launch Of Vibativ In Canada

Financial news for TBPH dated on 2015-12-10: Theravance Biopharma Reports Initial Patient Dosed In Phase 1 Trial Of TD-1473

Financial news for TBPH dated on 2015-12-08: Theravance Biopharma Doses Initial Patient In Phase 1 Clinical Of TD-0714, Company's neprilysin Inhibitor Program

Financial news for TBPH dated on 2015-11-09: Theravance Biopharma Reports Q3 EPS \$(1.40) vs. Est. \$(1.44), Rev. \$10.7M vs. Est. \$4.24M

Financial news for TBPH dated on 2015-11-02: Theravance Biopharma Submits Investigational New Drug Application for TD-1473, a GI-Targeted Pan-Janus Kinase Inhibitor

Financial news for TBPH dated on 2015-10-27: Theravance Biopharma and Trek Therapeutics Report Initiation of Phase 2a Trial of TD-6450, an NS5A Inhibitor to Treat Hepatitis C

Financial news for TBPH dated on 2015-10-26: Woodford Investment Management Acquires 3.859M Shares Of Theravance Biopharma For \$14.25/Share

Financial news for TBPH dated on 2015-10-12: Data From New Retrospective Studies of VIBATIV(R) (Telavancin) Demonstrate Positive Clinical Outcomes for Patients With Difficult-to-Treat, Gram-Positive Infections, Including MRSA

Financial news for TBPH dated on 2015-10-05: Theravance Biopharma to Show New Retrospective Clinical Data on VIBATIV Showing Positive Outcomes for Patients With Difficult-to-Treat Infections, Including MRSA, at IDWeek 2015

Financial news for TBPH dated on 2015-09-21: Data From New Studies Confirm In Vitro Potency of VIBATIV Against Gram-Positive Bacteria, Including MRSA

Financial news for TBPH dated on 2015-09-14: Theravance Biopharma, Mylan Report Initiation of Phase 3 Program for Revefenacin for the Treatment of COPD

Financial news for TBPH dated on 2015-09-10: Theravance Biopharma Presents Positive Clinical Data on Fixed-Dose Combination of Axelopran and Oxycodone at PAINWeek 2015

Financial news for TBPH dated on 2015-09-10: Theravance Biopharma Report FDA Acceptance of sNDA to Expand VIBATIV Labeling

Financial news for TBPH dated on 2015-09-08: Theravance Biopharma to Present New Data Highlighting in vitro Potency of VIBATIV(R) (telavancin) Against Gram-Positive Bacteria, Including MRSA, at 2015 ICAAC

Financial news for TBPH dated on 2015-09-02: GlaxoSmithKline Holder Theravance Reports 24.5% Stake As Of Dec 31

Financial news for TBPH dated on 2015-08-10: Theravance Biopharma Reports Q2 Loss \$1.42 vs Est Loss \$1.51, Sales \$7.13M Vs Est \$4.25M

Financial news for TBPH dated on 2015-07-23: Theravance Biopharma Reports Health Canada Approval for VIBATIV(R) (telavancin) for Treatment of HAP/VAP Caused by Gram-Positive Bacteria, Including MRSA

Financial news for TBPH dated on 2015-06-30: Theravance Biopharma Reports Marketing Authorization for VIBATIV(R) in Russia for Treatment of Multiple Infections Caused by Gram-Positive Bacteria

Financial news for TBPH dated on 2015-05-27: SciClone Pharmaceuticals, Theravance Biopharma Enter Development & Commercialization Agreement for VIBATIV (Telavancin) in China

Financial news for TBPH dated on 2015-05-20: Theravance Biopharma Presents Additional Positive Phase 2b Study Data on TD-4208

Financial news for TBPH dated on 2015-05-18: Theravance Biopharma Presents Positive Phase 2 Study Data on Velusetragfor Treatment of Gastroparesis

Financial news for TBPH dated on 2015-04-16: Theravance Biopharma Presents New Data Highlighting in vitro Potency of VIBATIV(R) (telavancin) Against Multidrug-Resistant Gram-Positive Bacteria, Including MRSA, at 2015 ECCMID Conference

Financial news for TBPH dated on 2015-03-10: Theravance Reports Q4 Loss of \$2.02/Share vs Loss of \$1.70/Share Est.

Financial news for TBPH dated on 2015-02-24: Theravance Biopharma Reports Enrollment of First Patient in Phase 3 Registrational Study of Telavancin in Staphylococcus Aureus Bacteremia

Financial news for TBPH dated on 2015-02-10: Theravance Biopharma Initiates Patient Registry Study for VIBATIV

Financial news for TBPH dated on 2015-02-02: Benzinga's Volume Movers

Financial news for TBPH dated on 2015-02-02: Theravance, Mylan Partner to Develop and Commercialize Novel LAMA Compound, TD-4208, for COPD

Financial news for TBPH dated on 2014-12-31: 19 Lesser-Known Biotech Stocks With Robust Drug Pipelines

Financial news for TBPH dated on 2014-11-06: Theravance Biopharma Reports Q3 EPS of \$(1.72) vs \$(1.85) Est; Revenue of \$6.30M vs \$1.49M Est

Financial news for TBPH dated on 2014-11-04: Morning Market Movers

Financial news for TBPH dated on 2014-11-04: Benzinga's Top #PreMarket Gainers

Financial news for TBPH dated on 2014-11-03: Theravance Biopharma Announces Positive Results From Phase 1 Proof-of-Concept Study of TD-6450

Financial news for TBPH dated on 2014-09-09: Theravance Biopharma Provides VIBATIV (telavancin) Product Update

Financial news for TBPH dated on 2014-09-08: Theravance Biopharma Announces Positive Top-Line Results from Phase 2b Dose-Ranging Study of its Investigational LAMA, TD-4208, for the Treatment of COPD

Financial news for TBPH dated on 2014-08-14: Benzinga's Top Downgrades

Financial news for TBPH dated on 2014-08-14: Baird Downgrades Theravance Biopharma To Underperform

Financial news for TBPH dated on 2014-08-14: Baird Downgrades Theravance Biopharma to Underperform, Maintains \$21.00 PT

Financial news for TBPH dated on 2014-08-13: Theravance Biopharma Reports Q2 EPS of \$(1.83); Revenue of \$2.97M

Financial news for TBPH dated on 2014-06-06: Bank of America Initiates Coverage on Theravance Biopharma at Buy, Announces \$34.00 PT